Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / ARVN - C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach

ARVN - C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach

Arvinas Inc.
  • C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders.
  • Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degraders.
  • In preclinical trials, C4's molecule has done better than Pomalyst in MM xenograft.

For further details see:

C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated Approach
Stock Information
Company Name: Arvinas Inc.
Stock Symbol: ARVN
Market: NASDAQ
Website: arvinas.com
Menu
ARVN ARVN Quote ARVN Short ARVN News ARVN Articles ARVN Message Board
Get ARVN Alerts

News, Short Squeeze, Breakout and More Instantly...